NeuroStar vs EXOMIND

Independent side-by-side comparison with pricing, specs, and clinical evidence.

Why This Comparison Matters

NeuroStar and EXOMIND sit in the same tms devices category but take different approaches. NeuroStar (Neuronetics) uses Transcranial Magnetic Stimulation (focused figure-8 coil) while EXOMIND (BTL Industries) uses ExoTMS (patented external TMS with proprietary coil design). Both received FDA clearance (2008 and 2024 respectively) and both are actively sold in the US market. The decision between them is rarely about which is objectively better. It's about which fits your specific practice.

Physicians end up comparing these two devices when they're shopping in the $80,000-$150,000 to $100,000-$200,000 price range and want a category leader. Both devices are commonly recommended by sales reps from competing manufacturers, which means physicians often hear inflated claims about one and dismissive claims about the other. This comparison strips out the marketing and looks at pricing, mechanism, evidence, and practice fit side by side.

Side-by-Side Specifications

NeuroStar EXOMIND
Manufacturer Neuronetics BTL Industries
Technology Transcranial Magnetic Stimulation (focused figure-8 coil) ExoTMS (patented external TMS with proprietary coil design)
Price (New) $80,000-$150,000 $100,000-$200,000
Price (Used) $40,000-$80,000 Limited secondary market (too new)
Treatment Time 19-37 minutes per session Under 30 minutes per session
Sessions 36 sessions over 9 weeks (standard protocol) 6 sessions (significantly fewer than competitors)
Per Session $300-$500 (insurance reimbursable) TBD (emerging pricing)
Annual Consumables $2,000-$5,000 (treatment caps) TBD
Annual Maintenance $5,000-$10,000 TBD
FDA Cleared Yes (2008) Yes (2024)

Technology

NeuroStar

Technology: Transcranial Magnetic Stimulation (focused figure-8 coil). First FDA-cleared TMS system. Largest clinical outcomes registry (over 5M treatments delivered). FDA-cleared for MDD, OCD, and anxious depression.

EXOMIND

Technology: ExoTMS (patented external TMS with proprietary coil design). FDA-cleared for depression in just 6 sessions (vs 20-36 for competitors). Also cleared in Canada/EU for anxiety, OCD, and binge eating.

Pricing

NeuroStar

New: $80,000-$150,000. Used: $40,000-$80,000. Per session: $300-$500 (insurance reimbursable). Annual consumables: $2,000-$5,000 (treatment caps). Annual maintenance: $5,000-$10,000.

EXOMIND

New: $100,000-$200,000. Used: Limited secondary market (too new). Per session: TBD (emerging pricing). Annual consumables: TBD. Annual maintenance: TBD.

Clinical Evidence

NeuroStar

Strongest in category. 100+ published studies. 5M+ treatment outcomes registry. Multiple FDA clearances backed by large RCTs.

EXOMIND

Emerging. FDA clearance data is available. Full peer-reviewed evidence base still developing.

Treatment Experience

NeuroStar

19-37 minutes per session per session. Recommended protocol: 36 sessions over 9 weeks (standard protocol). Treatment areas: Left dorsolateral prefrontal cortex. Patients typically tolerate this platform well when operated by trained clinicians.

EXOMIND

Under 30 minutes per session per session. Recommended protocol: 6 sessions (significantly fewer than competitors). Treatment areas: Dorsolateral prefrontal cortex. Patient experience varies by operator training and settings.

Practice Fit

NeuroStar

Psychiatrists starting a TMS practice who want the most established platform with the strongest insurance reimbursement track record. Practices that value the largest clinical dataset.

EXOMIND

Psychiatrists or multi-specialty practices already in the BTL ecosystem. Early adopters willing to bet on the 6-session protocol advantage.

Pros and Cons

NeuroStar Pros

  • First-mover advantage: largest installed base in the US
  • 5M+ treatments delivered (largest outcomes registry)
  • Insurance reimbursement well-established for NeuroStar
  • FDA-cleared for MDD, OCD, and anxious depression

NeuroStar Cons

  • Standard TMS depth (~2cm) vs BrainsWay's deep TMS (~6cm)
  • 36-session standard protocol requires significant patient commitment
  • Per-treatment cap fees reduce margins at high volume

EXOMIND Pros

  • Only 6 sessions required (vs 20-36 for NeuroStar/BrainsWay)
  • BTL's sales and support infrastructure
  • Potential for anxiety, OCD, binge eating clearances in US
  • Cross-sell path for existing BTL aesthetic practices

EXOMIND Cons

  • Brand new to market (2024 FDA clearance)
  • Limited published clinical evidence vs established competitors
  • Pricing not yet stabilized

The Verdict

Choose NeuroStar if your practice prioritizes Neuronetics's ecosystem, brand recognition, or specific clinical advantages. Psychiatrists starting a TMS practice who want the most established platform with the strongest insurance reimbursement track record. Practices that value the largest clinical dataset. The pros that matter most: First-mover advantage: largest installed base in the US; 5M+ treatments delivered (largest outcomes registry). The biggest tradeoff to accept: Standard TMS depth (~2cm) vs BrainsWay's deep TMS (~6cm).

Choose EXOMIND if BTL Industries's positioning fits better. Psychiatrists or multi-specialty practices already in the BTL ecosystem. Early adopters willing to bet on the 6-session protocol advantage. The pros that matter most: Only 6 sessions required (vs 20-36 for NeuroStar/BrainsWay); BTL's sales and support infrastructure. The biggest tradeoff to accept: Brand new to market (2024 FDA clearance).

For a practice with limited capital that needs maximum flexibility, used pricing tilts the math. NeuroStar used units run $40,000-$80,000; EXOMIND used units run Limited secondary market (too new). For practices with strong patient flow already, the device that integrates with your existing platforms is usually the right answer even if its standalone specs are slightly weaker. For practices building a category from scratch, brand recognition and patient demand matter more than raw clinical specs. Look at which device patients are already asking for in your market before signing a contract.

Frequently Asked Questions

Which is more expensive, NeuroStar or EXOMIND?

NeuroStar runs $80,000-$150,000 new and $40,000-$80,000 used. EXOMIND runs $100,000-$200,000 new and Limited secondary market (too new) used. Per-session pricing is $300-$500 (insurance reimbursable) for NeuroStar and TBD (emerging pricing) for EXOMIND. Annual operating costs (consumables plus maintenance) typically run 5-15% of purchase price for both devices. The right financial comparison includes total cost of ownership over 5 years, not just sticker price.

Which has better clinical evidence, NeuroStar or EXOMIND?

NeuroStar clinical evidence: Strongest in category. 100+ published studies. 5M+ treatment outcomes registry. Multiple FDA clearances backed by large RCTs. EXOMIND clinical evidence: Emerging. FDA clearance data is available. Full peer-reviewed evidence base still developing. Evidence quality is not just about study count. Look at sample sizes, blinded evaluators, independence from manufacturer funding, and outcome durability. Older devices in the same category usually have stronger evidence simply because they've been studied longer.

Is NeuroStar or EXOMIND more popular in psychiatry practices?

Both NeuroStar and EXOMIND are commonly used in psychiatry, neurology practices. Market share in any given category shifts year to year. Neuronetics and BTL Industries both maintain active sales forces in the US. Ask other physicians in your specialty which platform they're using and why. Peer references in your local market matter more than national market share data.

Are there safety concerns with NeuroStar or EXOMIND?

Both devices are FDA cleared and have established safety profiles. NeuroStar has these documented concerns: Standard TMS depth (~2cm) vs BrainsWay's deep TMS (~6cm). EXOMIND has: Brand new to market (2024 FDA clearance). Physicians should monitor FDA MAUDE reports for both devices before purchase. Adverse event trends matter because they signal problems that may not appear in marketing materials. Any device with a sudden spike in MAUDE filings deserves closer scrutiny.

Can I use NeuroStar and EXOMIND in the same practice?

Some practices run both devices, especially when they target different patient segments or treatment areas. The downside is duplicated training, parallel consumable inventories, and potential cannibalization between platforms. The upside is broader marketing claims and the ability to switch patients between platforms if one doesn't deliver expected results. Most practices choose one and commit to mastering it rather than splitting volume.

What's the resale value comparison between NeuroStar and EXOMIND?

Used NeuroStar sells for $40,000-$80,000 on the secondary market. Used EXOMIND sells for Limited secondary market (too new). Resale values depend on age, software version, applicator condition, and remaining warranty. Devices with strong installed bases hold value better. Devices with active safety signals or declining manufacturer financial health depreciate faster. Resale value should be a factor in any device purchase, especially if practice plans might change in 3-5 years.